OxThera has raised €32 million for a treatment for hyperoxaluria, a urinary condition that can cause kidney stones. Lead investors were Life Sciences Partners, Ysios Capital, Sunstone Capital and Flerie Invest, alongside Kurma Partners, Idinvest Partners, Stiftelsen Industrifonden and Brohuvudet...
Read More on penews.com (subscription required)